# Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

> **NCT03094637** · PHASE2 · UNKNOWN · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- High Risk Myelodysplastic Syndrome
- IPSS Risk Category Intermediate-1
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Azacitidine
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03094637
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-06
- **Primary completion:** 2021-11-06
- **Final completion:** 2023-11-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03094637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03094637, "Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03094637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*